OBIO
Orchestra BioMed Holdings, Inc. NASDAQ Listed Aug 4, 2020$3.99
+3.10%
vs $3.87
Mkt Cap $153.2B
52w Low $2.35
54.7% of range
52w High $5.35
50d MA $4.06
200d MA $3.97
P/E (TTM)
-3.6x
EV/EBITDA
—
P/B
2347.1x
Debt/Equity
0.0x
ROE
-52.8%
P/FCF
-3097.7x
RSI (14)
53.80
ATR (14)
$0.19
Beta
0.60
50d MA
$4.06
200d MA
$3.97
Avg Volume
258.6K
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
150 Union Square Drive · New Hope, PA 18938 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | BMO | -0.40 | -0.33 | +17.5% | 3.91 | -0.3% | +3.8% | +0.0% | +1.2% | -9.5% | +7.0% | — |
| May 8, 2026 | BMO | — | — | — | 3.93 | +1.5% | +2.8% | -3.2% | +3.8% | +0.0% | +1.2% | — |
| Mar 12, 2026 | BMO | -0.38 | 0.26 | +168.4% | 4.38 | +0.0% | -4.1% | +8.3% | +1.3% | -2.2% | +2.9% | — |
| Nov 10, 2025 | BMO | -0.38 | -0.40 | -5.3% | 3.78 | -0.8% | +8.5% | +7.8% | -5.4% | -5.7% | +4.8% | — |
| Aug 12, 2025 | BMO | -0.51 | -0.50 | +2.0% | 2.72 | -0.7% | -2.2% | +0.0% | -3.4% | +2.3% | -3.0% | — |
| Apr 2, 2025 | BMO | -0.43 | -0.43 | +0.0% | 3.52 | -8.8% | -11.6% | -11.3% | +2.5% | -1.4% | +5.0% | — |
| Mar 26, 2025 | BMO | -0.43 | -0.37 | +14.0% | 4.38 | +4.1% | +5.0% | -4.3% | -2.7% | -24.3% | +8.6% | — |
| Nov 12, 2024 | BMO | -0.44 | -0.41 | +6.8% | 5.66 | +5.8% | +7.2% | +2.3% | -6.0% | -0.2% | -11.3% | — |
| Aug 12, 2024 | BMO | -0.41 | -0.45 | -9.8% | 6.11 | +2.3% | -2.5% | -7.0% | +9.4% | +5.9% | -0.5% | — |
| May 13, 2024 | BMO | -0.40 | -0.38 | +5.0% | 4.60 | +0.0% | +13.0% | -7.5% | -4.0% | +12.8% | +0.4% | — |
| Mar 27, 2024 | BMO | -0.38 | -0.37 | +2.6% | 5.31 | -1.3% | -0.8% | -6.1% | +1.8% | -2.8% | +1.4% | — |
| Nov 13, 2023 | BMO | -0.39 | -0.38 | +2.6% | 6.04 | -4.0% | +13.1% | +4.2% | -2.0% | -2.7% | -0.7% | — |
| Aug 10, 2023 | BMO | -0.42 | -0.35 | +16.7% | 6.07 | +1.6% | -1.6% | -1.7% | -3.9% | -5.3% | +2.4% | — |
| May 12, 2023 | AMC | -0.28 | -0.40 | -42.9% | 17.00 | +2.8% | +2.5% | -2.8% | +15.6% | -19.0% | -4.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $4.60 | $4.61 | +0.2% | -4.8% | -4.1% | +8.3% | +1.3% | -2.2% |
| Jan 9 | Barclays | Maintains | Overweight → Overweight | — | $4.84 | $4.96 | +2.5% | -0.8% | -2.9% | -8.2% | +4.2% | -6.5% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $4.42 | $4.38 | -0.9% | -5.4% | -5.7% | +4.8% | +2.4% | +10.2% |
| Nov 12 | Barclays | Maintains | Overweight → Overweight | — | $4.10 | $4.17 | +1.7% | +7.8% | -5.4% | -5.7% | +4.8% | +2.4% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.72 | $2.73 | +0.4% | +0.7% | +0.4% | -0.7% | -0.7% | -3.7% |
| Aug 20 | BTIG | Downgrade | Buy → Neutral | — | $2.55 | $2.56 | +0.4% | -4.7% | +2.5% | +2.4% | +2.0% | +15.4% |
| Aug 13 | Chardan Capital | Maintains | Buy → Buy | — | $2.72 | $2.70 | -0.7% | -2.2% | +0.0% | -3.4% | +2.3% | -3.0% |
| Aug 7 | Chardan Capital | Maintains | Buy → Buy | — | $2.64 | $2.68 | +1.5% | -1.5% | +4.2% | -7.0% | +7.9% | -2.2% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $2.65 | $2.72 | +2.6% | +10.9% | -4.1% | +2.5% | +0.3% | +0.7% |
| May 5 | Barclays | Maintains | Overweight → Overweight | — | $2.74 | $2.66 | -2.9% | -6.6% | -5.5% | +1.7% | +16.7% | -7.7% |
| Apr 22 | Chardan Capital | Maintains | Buy → Buy | — | $2.84 | $3.13 | +10.2% | +0.7% | -0.3% | -9.5% | +7.8% | -6.1% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.11 | $2.96 | -4.8% | -11.3% | +2.5% | -1.4% | +5.0% | -11.3% |
| Apr 1 | Chardan Capital | Maintains | Buy → Buy | — | $4.28 | $3.86 | -9.8% | -24.3% | +8.6% | -11.6% | -11.3% | +2.5% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.23 | $4.16 | -1.7% | -6.1% | +0.8% | +0.5% | -4.5% | +6.2% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.21 | $6.25 | +0.6% | -6.0% | -0.2% | -11.3% | +2.1% | +3.0% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $5.66 | $5.99 | +5.8% | +7.2% | +2.3% | -6.0% | -0.2% | -11.3% |
| Jun 12 | Chardan Capital | Maintains | Buy → Buy | — | $7.96 | $8.14 | +2.3% | -0.3% | -1.5% | +1.9% | +0.9% | -7.5% |
| Mar 28 | Chardan Capital | Maintains | Buy → Buy | — | $5.31 | $5.24 | -1.3% | -0.8% | -6.1% | +1.8% | -2.8% | +1.4% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $6.07 | $6.17 | +1.6% | -1.6% | -1.7% | -3.9% | -5.3% | +2.4% |
| Aug 9 | Chardan Capital | Maintains | Buy → Buy | — | $5.54 | $5.79 | +4.5% | +2.3% | +7.1% | -1.6% | -1.7% | -3.9% |
| May 15 | Chardan Capital | Maintains | Buy → Buy | — | $17.00 | $17.47 | +2.8% | +2.5% | -2.8% | +15.6% | -19.0% | -4.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Sherman DarrenDir/Off | See Remarks | Sell | 15,000 | $3.87 | $58K | 1,184,327 | -1.28% | +2.03% |
| Jun 1, 2026 | Hochman David PDir/Off | See Remarks | Buy | 5,000 | $3.83 | $19K | 1,064,029 | -1.28% | +2.03% |
| May 18, 2026 | Aryeh JasonDir | — | Buy | 665 | $3.75 | $2K | 118,118 | +3.02% | +0.76% |
| May 15, 2026 | Aryeh JasonDir | — | Buy | 8,971 | $3.90 | $35K | 117,453 | -0.50% | -0.50% |
| May 15, 2026 | Hochman David PDir/Off | See Remarks | Buy | 5,000 | $3.77 | $19K | 1,059,029 | -0.50% | -0.50% |
| May 14, 2026 | Fain Eric SDir | — | Buy | 20,000 | $4.13 | $83K | 91,709 | +0.50% | -2.22% |
| Apr 27, 2026 | RTW INVESTMENTS, LP | — | Sell | 32 | $4.13 | $132 | 9,556,063 | +5.00% | +2.49% |
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 8,306,063 | $35M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 2,204,319 | $9M | New | Mar 2026 |
| 3 | Alyeska Investment Group, L.p. | 1,000,000 | $4M | — | Mar 2026 |
| 4 | Propel Bio Management, Llc | 896,701 | $4M | New | Mar 2026 |
| 5 | Millennium Management | 702,543 | $3M | Added | Mar 2026 |
| 6 | Knott David M Jr | 253,651 | $1M | Added | Mar 2026 |
| 7 | Marshall Wace, Llp | 188,484 | $801K | Added | Mar 2026 |
| 8 | Jane Street Group, Llc | 173,765 | $721K | Added | Dec 2025 |
| 9 | Morgan Stanley | 163,702 | $679K | Added | Dec 2025 |
| 10 | Northern Trust Corp | 118,274 | $503K | Added | Mar 2026 |
| 11 | Qube Research & Technologies Ltd | 108,953 | $463K | Added | Mar 2026 |
| 12 | Ifp Advisors, Inc | 98,887 | $420K | Added | Mar 2026 |
| 13 | Susquehanna International Group, Llp | 97,521 | $414K | Reduced | Mar 2026 |
| 14 | Point72 Asset Management | 87,888 | $374K | Reduced | Mar 2026 |
| 15 | Citadel Advisors Llc | 79,185 | $337K | Added | Mar 2026 |
| 16 | Renaissance Technologies Llc | 70,900 | $301K | Reduced | Mar 2026 |
| 17 | Two Sigma Investments, Lp | 60,107 | $255K | Reduced | Mar 2026 |
| 18 | Barclays Plc | 59,342 | $252K | Reduced | Mar 2026 |
| 19 | Daytona Street Capital Llc | 52,600 | $235K | Added | Mar 2026 |
| 20 | Bank Of America Corp /de/ | 52,761 | $224K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 15
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | BlackRock Health Sciences Opportunities Portfolio | 206,130 | $903K | Feb 2026 |
| 2 | Fidelity Extended Market Index Fund | 206,081 | $903K | Feb 2026 |
| 3 | Schwab U.S. Small-Cap ETF | 181,156 | $793K | Feb 2026 |
| 4 | iShares Micro-Cap ETF | 100,807 | $428K | Mar 2026 |
| 5 | Fidelity Total Market Index Fund | 72,838 | $319K | Feb 2026 |
| 6 | Ultra-Small Company Market Fund | 63,500 | $270K | Mar 2026 |
| 7 | Fidelity Series Total Market Index Fund | 57,348 | $251K | Feb 2026 |
| 8 | Fidelity Nasdaq Composite Index Fund | 49,166 | $215K | Feb 2026 |
| 9 | Schwab U.S. Broad Market ETF | 43,157 | $189K | Feb 2026 |
| 10 | Schwab Total Stock Market Index Fund | 40,496 | $141K | Jan 2026 |
| 11 | Small Cap Core Fund | 10,074 | $43K | Mar 2026 |
| 12 | Avantis U.S. Small Cap Equity ETF | 3,182 | $14K | Feb 2026 |
| 13 | Invesco Nasdaq Biotechnology ETF | 3,155 | $14K | Feb 2026 |
| 14 | ProShares Ultra Nasdaq Biotechnology | 2,607 | $11K | Feb 2026 |
| 15 | Knights of Columbus U.S. ALL CAP INDEX FUND | 195 | $681 | Jan 2026 |
Valuation
Market Cap
$153.19B
Enterprise Value
$153.08B
P/E (TTM)
-3.59x
Forward P/E
—
PEG Ratio
90.81x
P/B
2347.06x
P/S
4575.20x
P/FCF
-3097.69x
EV/EBITDA
—
Shares Out
38.39B
Financials (TTM)
Revenue
$33.5M
Net Income
-$53.0M
EBITDA
-$51.5M
Free Cash Flow
-$49.5M
Op Cash Flow
-$49.0M
EPS Basic
$-1.11
EPS Diluted
$-1.11
EPS Forward
$-1.77
Gross Margin
99.4%
Op Margin
-154.7%
Net Margin
-158.2%
Balance Sheet
Total Assets
$114.9M
Total Liab.
$51.5M
Total Equity
$63.4M
Cash
$106.5M
LT Debt
$936K
Book Value/Sh
$0.00
Debt/Equity
0.03x
Current Ratio
6.45
Quick Ratio
6.43
Returns & Growth
ROE
-52.8%
ROA
-45.9%
ROIC
-52.4%
Rev Growth YoY
+1169.2%
EPS Growth YoY
+33.1%
Price Returns
2W
-4.9%
1M
-2.0%
3M
-10.7%
6M
-26.5%
12M
+37.2%
Technicals
52W High
$5.35
52W Low
$2.35
50d MA
$4.06
200d MA
$3.97
RSI (14)
53.80
ATR (14)
$0.19
Beta
0.60
Avg Volume
259K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 26, 2026 4:46pm
· Source: financialmodelingprep.com